Showing 5061-5070 of 9772 results for "".
- Dr. Mario E. Lacouture Named New Chief of Dermatology at NYU Langone Hospital--Long Islandhttps://practicaldermatology.com/news/dr-mario-e-lacouture-named-new-chief-of-dermatology-at-nyu-langone-hospital-long-island/2462164/Mario E. Lacouture, MD, has been named the new Chief of the Dermatology Division, Department of Medicine of NYU Langone Hospital--Long Island. Dr. Lacouture will receive an academic appointment as Professor of Medicine at NYU Grossman School of Medicine, and will serve as the Medic
- Regenerative Medicine in Action: Reprogramming Tissue Mechanically to Heal Wounds, Rejuvenate Skinhttps://practicaldermatology.com/news/regenerative-medicine-in-action-reprogramming-tissue-mechanically-to-heal-wounds-rejuvenate-skin/2462156/Researchers have taken connective tissue cells that have been mechanically reprogrammed to resemble stem cells and transplanted them into damaged skin. In their laboratory experiment, they were able to show that the skin tissue model can actually be rejuvenated and that injur
- FDA Grants Priority Review for Abeona's Pz-cel BLAhttps://practicaldermatology.com/news/fda-grants-priority-review-for-abeonas-pz-cel-bla/2462154/The U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review for the Biologics License Application (BLA) of Abeona Therapeutics Inc.’s pz-cel (prademagene zamikeracel), an investigational autologous, COL7A1 gene-corrected epidermal sheets for the treatment of patient
- First Patients Enrolled in Phase 2 Proof of Concept Trial of MC2-25 VLS in Vulvar Lichen Sclerosushttps://practicaldermatology.com/news/first-patients-enrolled-in-phase-2-proof-of-concept-trial-of-mc2-25-vls-in-vulvar-lichen-sclerosus/2462151/The first patients have been enrolled in a Phase 2a proof of concept trial evaluating the safety and efficacy of MC2-25 VLS, a new drug candidate for the treatment of urea- associated skin diseases, including vulvar lichen sclerosus. MC2-25 VLS is a based on a di-peptide that
- Take That, Melanoma! ATM Kinase Inhibitors May Stop Metastasishttps://practicaldermatology.com/news/take-that-melanona-atm-kinase-inhibitors-may-stop-metastasis/2462146/Ataxia telangiectasia mutated (ATM) kinase inhibition may target the metastatic capacity of melanoma cells, according to a research team led by Wolfgang Weninger and Shweta Tikoo from MedUni Vienna's Department of Dermatology. The results of the study, which appe
- Strength in Numbers: IPC, IFPA, and ILDS Presidents Sign Letter of Commitmenthttps://practicaldermatology.com/news/strength-in-numbers-ipc-ifpa-and-ilds-presidents-sign-letter-of-commitment/2462144/Hervé Bachelez, MD, PhD, President of the International Psoriasis Council (IPC), Hoseah Waweru, MD, President of the International Federation of Psoriasis Associations (IFPA), and Henry W. Lim MD, President of the International League of Dermatological Societies (ILDS) recently signed a le
- Ichthyosis Linked to Mood Disordershttps://practicaldermatology.com/news/ichthyosis-linked-to-mood-disorders/2462139/People living with Ichthyosis may be at higher risk for mental health conditions like depression and anxiety, according to a recent study in the Journal of the American Academy of Dermatology. Re
- Scientists 3D-print Hair Follicles in Lab-grown Skinhttps://practicaldermatology.com/news/scientists-3d-print-hair-follicles-in-lab-grown-skin/2462137/Scientists at Rensselaer Polytechnic Institute have 3D-printed hair follicles in human skin tissue cultured in the lab. This marks the first time that researchers have used the technology to generate hair follicles. The findings appear in
- Ankyra Therapeutics and Regeneron to Evaluate ANK-101 in Combination with Cemiplimab in Patients CSCChttps://practicaldermatology.com/news/ankyra-therapeutics-and-regeneron-to-evaluate-ank-101-in-combination-with-cemiplimab-in-patients-cscc/2462132/Ankyra Therapeutics will be working with Regeneron to evaluate ANK-101 in combination with Regeneron’s anti-PD-1 therapy, Libtayo (cemiplimab) in patients with cutaneous squamous cell carcinoma (CSCC) via a new a clinical trial supply agreement. ANK-101 is a novel first-
- FDA Accepts sBLA for Interchangeability Designation for Hadlima, a Humira Biosimilarhttps://practicaldermatology.com/news/fda-accepts-sbla-for-interchangeability-designation-for-hadlima-a-biosimilar-to-humira/2462131/The U.S. Food and Drug Administration (FDA) has accepted the Supplemental Biologics License Application (sBLA) for the interchangeability designation or Hadlima (adalimumab-bwwd) injection 40 mg/0.4 mL, a biosimilar to Humira(adalimumab). Once a biosimilar product is designated as an in